The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

A group of Democratic senators are calling on Health and Human Services Secretary Robert F. Kennedy Jr. to keep a proposed ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

A decision by CMS to not move forward with a proposed rule allowing obesity medications to be covered under Medicare Part D ...

Democrat senators are begging Health and Human Services Secretary (HHS) Robert F. Kennedy Jr. to keep a proposed Biden-era rule pertaining to obesity drugs. In November, the […] ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

The Trump administration has declined to cover expensive, high-demand obesity treatments under the federal government’s Medicare program, Tom ...

The Biden administration sought to sidestep this obstacle by issuing a rule in November reinterpreting existing statutes to allow for Medicare Part D to cover anti-obesity drugs. But earlier this ...